📰 Nasdaq Lrmr News
Nasdaq Lrmr News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Lrmr. Real-time updates on events, politics, business and more.
April 11, 2024
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have been given an average rating of “Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued ratings on the […]
February 29, 2024
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report)’s stock price dropped 4.8% during mid-day trading on Tuesday . The stock traded as low as $11.76 and last traded at $11.80. Approximately 33,993 shares changed hands during trading, a decline of 95% from the average daily volume of 625,641 shares. The stock had previously closed at […]
February 17, 2024
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) rose 7% during trading on Thursday . The stock traded as high as $13.17 and last traded at $12.80. Approximately 263,608 shares traded hands during trading, a decline of 49% from the average daily volume of 520,626 shares. The stock had previously closed at $11.96. […]
February 17, 2024
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report)’s stock price was up 7% on Thursday . The company traded as high as $13.17 and last traded at $12.80. Approximately 263,608 shares changed hands during trading, a decline of 49% from the average daily volume of 520,626 shares. The stock had previously closed at $11.96. Analyst […]
February 13, 2024
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its price target upped by equities research analysts at Citigroup from $4.50 to $10.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target would indicate a potential upside of 2.56% from the company’s current price. […]
November 17, 2023
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) was upgraded by stock analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued on Friday, Marketbeat reports. The brokerage currently has a $4.50 price target on the stock. Citigroup’s target price points to a potential upside of 45.63% from the company’s […]
November 17, 2023
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat reports. The firm currently has a $4.50 target price on the stock. Citigroup’s target price points to a potential upside […]
May 19, 2023
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) – Equities research analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Tuesday, May 16th. William Blair analyst M. Minter forecasts that the company will earn ($0.22) per share for the quarter. The consensus estimate for […]
May 18, 2023
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the stock in a transaction on Wednesday, May 17th. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $10,257.50. Following the completion of the acquisition, the director now owns 2,750 shares of the […]
May 18, 2023
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) CFO Michael Celano purchased 5,000 shares of the stock in a transaction dated Wednesday, May 17th. The stock was bought at an average cost of $3.73 per share, with a total value of $18,650.00. Following the completion of the purchase, the chief financial officer now owns 112,746 shares […]